AchE Inhibitor and Insulin
- Registration Number
- NCT03063515
- Lead Sponsor
- University of Miami
- Brief Summary
The investigator will examine the effect of a single dose of pyridostigmine, AchE inhibitor on insulin secretion in healthy subjects. Each subject will undergo an intravenous glucose tolerance test (IVGTT) where IV glucose will be administered and the glucose excursion and insulin secretion response will be evaluated by measuring insulin and glucose at different time points. The test will be carried out twice, once without and once with the administration of a single dose of Pyridostigmine on two separate days. The investigator hypothesizes that inhibiting AChE will potentiate insulin secretion.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
- 18 years and older
- BMI >30 Kg/m2
- fasting glucose >100
- Glycohemoglobin (Hemoglobin A1C) 5.7% or more
- History of asthma
- Use of medications that may interfere with glucose metabolism
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description IVGTT with pyridostigmine Pyridostigmine An IVGTT will be performed 2 hours after taking one single dose of pyridostigmine 60 mg
- Primary Outcome Measures
Name Time Method First phase insulin response to IV glucose infusion -10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes Insulin positive incremental area under the curve and the sum of plasma insulin values at 1 minute and 3 minutes after IV glucose infusion
- Secondary Outcome Measures
Name Time Method Glucose excursion after IV glucose infusion -10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes Glucose positive incremental area under the curve
Trial Locations
- Locations (1)
Diabetes Research Institute
🇺🇸Miami, Florida, United States